ImCheck shows breakthrough results in treating AML patients with ICT01
- ICT01 is being investigated as a treatment for newly diagnosed acute myeloid leukemia in older, unfit patients.
- Interim results from the EVICTION trial indicate that ICT01 combined with azacitidine and venetoclax generated high rates of complete remission.
- These findings suggest a significant step forward in the treatment options available for AML patients with poor prognoses.
In the recent poster presentation at the 66th American Society of Hematology Annual Meeting, ImCheck Therapeutics shared encouraging interim results from the EVICTION trial. This trial focuses on the use of ICT01, a novel T-cell activator, in combination with azacitidine and venetoclax for treating newly diagnosed acute myeloid leukemia (AML) in older or unfit patients. The data suggest that ICT01 was both safe and well-tolerated, resulting in high rates of complete remission across various molecular subgroups, particularly in patients with TP53 mutations. The EVICTION study is part of broader clinical research on ICT01 as a potential treatment for advanced solid and hematologic cancers that have not responded to standard therapies. The findings highlight the promise of immunotherapeutic strategies in enhancing treatment outcomes for AML, a disease historically associated with poor prognosis.